Mismatch repair deficient endometrial cancer

Mismatch repair deficient endometrial cancer is a molecularly defined subtype of uterine malignancy arising from the inner epithelial lining of the uterus This molecular defect prevents the physiological correction of replication errors, producing high microsatellite instability, an elevated tumor mutational burden, and prominent neoantigen expression Consequently, these tumors frequently exhibit dense tumor-infiltrating lymphocytes and represent an intermediate prognostic group with distinct re...

Mismatch repair deficient endometrial cancer is a molecularly defined subtype of uterine malignancy arising from the inner epithelial lining of the uterus This molecular defect prevents the physiological correction of replication errors, producing high microsatellite instability, an elevated tumor mutational burden, and prominent neoantigen expression

It predominantly affects adult female patients and is characterized by a loss of functional DNA mismatch repair machinery—typically involving the MLH1, MSH2, MSH6, or PMS2 proteins—secondary to somatic alterations such as *MLH1* promoter hypermethylation or germline mutations associated with Lynch syndrome

It predominantly affects adult female patients and is characterized by a loss of functional DNA mismatch repair machinery—typically involving the MLH1, MSH2, MSH6, or PMS2 proteins—secondary to somatic alterations such as *MLH1* promoter hypermethylation or germline mutations associated with Lynch syndrome

It predominantly affects adult female patients and is characterized by a loss of functional DNA mismatch repair machinery—typically involving the MLH1, MSH2, MSH6, or PMS2 proteins—secondary to somatic alterations such as *MLH1* promoter hypermethylation or germline mutations associated with Lynch syndrome

This molecular defect prevents the physiological correction of replication errors, producing high microsatellite instability, an elevated tumor mutational burden, and prominent neoantigen expression

Consequently, these tumors frequently exhibit dense tumor-infiltrating lymphocytes and represent an intermediate prognostic group with distinct responsiveness to systemic immunotherapies